Drug intelligence / Profile preview

Lancovutide

Development stage: Phase 2
Modality: Peptides
Administration: Inhalation

Overview

Lancovutide is an investigational peptide drug developed for the treatment of cystic fibrosis. It functions by activating chloride channels, specifically calcium-dependent chloride channels (CaCC) or TMEM-16A, which are distinct from the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This mechanism aims to promote chloride efflux and rehydrate airway mucus, thereby bypassing the underlying CFTR defect in cystic fibrosis patients. Clinical trials have investigated its efficacy and safety in adolescents and adults with cystic fibrosis via inhalation.

Other names: 兰瑞肽

Targets

PE (Phosphatidylethanolamine)

Beyond the preview

Go deeper on Lancovutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lancovutide.

Explore the full profile